Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function
- 31 May 2005
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 333 (1), 200-205
- https://doi.org/10.1016/j.bbrc.2005.05.098
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansionBlood, 2004
- RANKing c-Jun in osteoclast developmentJournal of Clinical Investigation, 2004
- RANK ligand and osteoprotegerin in myeloma bone diseaseBlood, 2003
- Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myelomaBlood, 2002
- Metastasis to bone: causes, consequences and therapeutic opportunitiesNature Reviews Cancer, 2002
- Immunocytochemistry reveals RANKL expression of myeloma cellsBlood, 2002
- RANK (receptor activator of nuclear factor‐κB) and RANKL expression in multiple myelomaBritish Journal of Haematology, 2002
- Receptor activator of nuclear factor-κB ligand and osteoprotegerinCancer, 2001
- Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand FamiliesEndocrine Reviews, 1999
- A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell functionNature, 1997